Relmada Therapeutics Inc (RLMD NASDAQ) stock market data APIs
$0.6737
-0.08(-11.9%)
as of July 10, 2025
Try our APIs with
free plan!
Relmada Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. It also develops REL-P11, a modified-release formulation of psilocybin that has completed Phase 1 safety study for the treatment of metabolic disease. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.
Prev. Close
0.6737
Open
0.5973
High
0.6962
Low
0.5973
52 wk Range
0.2404-4.37
Market Cap
24 341 K
Shares Outstanding
33 192 K
EPS
-0.58
Beta
0.656
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Relmada Therapeutics Inc data using free add-ons & libraries
Get Relmada Therapeutics Inc Fundamental Data
Relmada Therapeutics Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -161 247 824
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-23
- EPS/Forecast: -0.31
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Relmada Therapeutics Inc News
New
DIMERx Appoints Biotech Leader Sergio Traversa, PharmD, to Board of Directors
SAN FRANCISCO, July 09, 2025 (GLOBE NEWSWIRE) -- DIMERx, Inc., a late-stage clinical biopharmaceutical company developing covalently bonded dimer therapeutics, today announced the appointment of Ser...
Relmada Therapeutics Hires Raj S. Pruthi As Chief Medical Officer-Urology
(RTTNews) - Relmada Therapeutics, Inc. (RLMD)Tuesday said it has appointed Raj S. Pruthi as Chief Medical Officer-Urology (CMO). Pruthi is a physician-scientist with more than 25 years of experience ...
Relmada Therapeutics, Inc.'s (NASDAQ:RLMD) market cap touched US$109m last week, benefiting both individual investors who own 39% as well as institutions
Key Insights Relmada Therapeutics' significant individual investors ownership suggests that the key decisions are influenced by shareholders from the larger public 50% of the business is held by the ...
Health Care Roundup: Market Talk
Longboard Pharmaceuticals, Walgreens Boots Alliance and more in the latest Market Talks covering the Health Care sector. Continue reading
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
